Although direct evidence remains limited, preliminary findings suggest that incretin-based pharmacotherapy reduces circulating MMP-2 and MMP-9 levels [8,9], highlighting its potential to restore ECM homeostasis and attenuate chronic inflammation in obesity. This evidence concerns the gene MMP9 and obesity due to melanocortin 4 receptor deficiency.